

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	Unknown
Filing Date	Herewith
First Named Inventor	Porter et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UNMC/0014

Submission Date

January 22, 2004

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
A1	US-4,572,203		02/25/1986	Steven B. Feinstein	
A2	US-4,718,433		01/12/1988	Steven B. Feinstein	
A3	US-4,774,958		10/04/1988	Steven B. Feinstein	
A4	US-5,560,364		10/01/1996	Board of Regents of the University of Nebraska	
A5	US-5,567,415		10/22/1996	Board of Regents of the University of Nebraska	
A6	US-5,578,291		11/26/1996	Board of Regents of the University of Nebraska	
A7	US-5,701,899		12/30/1997	Board of Regents of the University of Nebraska	
A8	US-5,980,950		11/09/1999	Board of Regents of the University of Nebraska	
A9	US-6,080,386		06/27/2000	Board of Regents of the University of Nebraska	
A10	US-6,245,747		06/12/2001	Board of Regents of the University of Nebraska	
A11	US-6,439,236		08/27/2002	Board of Regents of the University of Nebraska	
A12	US-6,537,814		03/25/2003	Board of Regents of the University of Nebraska	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Number-Kind Code ² (if known)				
B1	EP 0398935 (WO 89/06978) A1		08/10/1989	Schering AG, Berlin und Bergkamen		
B2	EP 0441468 A2		08/14/1991	Schering AG, Berlin und Bergkamen		
B3	EP 0458079 A2		11/27/1991	Hoechst Aktiengesellschaft		
B4	EP 0458745 A1		11/27/1991	Sintetica S.A.		X
B5	WO 80/02365 A1		11/13/1980	Rasor Associates, Inc.		X
B6	WO 93/17718 A1		09/16/1993	Klaveness et al.		X
B7	WO 96/07434 A1		03/14/1996	Klaveness et al.		X
B8	WO 96/39197 A1		12/12/1996	IMARx Pharmaceutical Corp.		X
B9	WO 97/29783 A1		08/21/1997	Dugstad et al.		X
B10	WO 99/13918		03/25/1999	University of Pittsburgh		X

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

Application Number Unknown

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Filing Date Herewith

(Use as many sheets as necessary)

First Named Inventor Porter et al.

Sheet

2

of

2

Group Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number UNMC/0014

Submission Date January 22, 2004

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	Villanueva, Flordeliza S. et al. "Albumin Microbubble Adherence to Human Coronary Endothelium: Implications for Assessment of Endothelial Function Using Myocardial Contrast Echocardiography." <u>J. Am. Coll. Cardiol.</u> 1997, 30: 689-93.	
	2	Lindner, M.D., Jonathan R. et al. "Albumin Microbubble Persistence During Myocardial Contrast Echocardiography is Associated with Microvascular Endothelial Glycocalyx Damage." <u>Circulation</u> . 1998, 98: 2187-94.	
	3	Masugata, M.D., Hisashi et al. "Comparison of Microbubble Agents that Produce Different Myocardial Signal Intensity for Quantification of Myocardial Blood Flow by Myocardial Contrast Echo." <u>The American Journal of Cardiology</u> . September 2001, 88: 714-718.	
	4	Phillips, P.J. "Contrast Pulse Sequences (CPS): Imaging Nonlinear Microbubbles." <u>IEEE Ultrasonics Symposium</u> . 2001, 1739-45.	
	5	Venneri, Lucia et al. "Detection of Carotid Artery Endothelial Function with Intravenous Microbubbles." <u>The Online Abstract</u> . 2003.	
	6	Celermajer, David S. "Endothelial Dysfunction: Does It Matter? Is It Reversible?" <u>J. Am. Coll. Cardiol.</u> August 1997, 30(2): 325-33.	
	7	Fisher, MBBS, Nicholas G. et al. "Influence of Microbubble Surface Charge on Capillary Transit and Myocardial Contrast Enhancement." <u>J. Am. Coll. Cardiol.</u> 2002, 40(4): 811-9.	
	8	Kaul, S. "Instrumentation for contrast echocardiography: technology and techniques." <u>Am. J. Cardiol.</u> November 2002, 19(90 Suppl 10A:8J-14J. National Center for Biotechnology Information. 14 April 2003 <wysiwyg://http://www.ncbi.nlm.nih.gov...PubMed&List_uids=12450584&dopt=Abstract>.	
	9	Villanueva, F.S. et al. "Microbubble-endothelial cell interactions as a basis for assessing endothelial function." <u>Echocardiography</u> . July 2002, 19(5): 427-38. National Center for Biotechnology Information. 28 March 2003 <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12...>.	
	10	Lindner, M.D., Jonathan R. et al. "Microbubble Persistence in the Microcirculation During Ischemia/Reperfusion and Inflammation is Caused by Integrin- and Complement-Mediated Adherence to Activated Leukocytes." <u>Circulation</u> . 2000, 101: 668-75.	
	11	Lindner, M.D., Jonathan R. et al. "Noninvasive Ultrasound Imaging of Inflammation Using Microbubbles Targeted to Activated Leukocytes." <u>Circulation</u> . 2000, 102: 2745-50.	
	12	Klibanov, A.L. et al. "Targeting and ultrasound imaging of microbubble-based contrast agents." <u>Magma</u> . August 1999, 8(3): 177-84. National Center for Biotechnology Information. 28 March 2003. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10...>.	
	13	Lindner, M.D., Jonathan R. et al. "Ultrasound Assessment of Inflammation and Renal Tissue Injury with Microbubbles Targeted to P-Selectin." <u>Circulation</u> . 2001, 104: 2107-2112.	

Examiner

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.